DelveInsight’s, “HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Insight, 2023” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the HPV+ Recurrent/Metastatic Head and Neck Cancer pipeline landscape. It covers the HPV+ Recurrent/Metastatic Head and Neck Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Report

• DelveInsight’s HPV+ Recurrent/Metastatic Head and Neck Cancer pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for HPV+ Recurrent/Metastatic Head and Neck Cancer treatment.
• The leading companies working in the HPV+ Recurrent/Metastatic Head and Neck Cancer Market include BioNTech, Cue Biopharma, Hookipa Pharma, and others.
• Promising HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Therapies in the various stages of development include MEDI0457, Durvalumab, CUE-101, Keytruda, BNT113, Pembrolizumab, palbociclib, Cetuximab, and others.
• November 2023: BioNTech SE announced a study of Phase 2 clinical trials for BNT113 and Pembrolizumab. An open-label, controlled, multi-site, interventional, 2-arm, Phase II trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing programmed cell death ligand -1 (PD-L1) with combined positive score (CPS) ≥1.
• October 2023: Hookipa Biotech GmbH announced a study of Phase 1 & 2 clinical trials for HB-201 intravenous administration. This is a First in Human (FIH) Phase I/II, multinational, multicenter, open-label study of HB-201 single vector therapy and HB-201 & HB-202 two-vector therapy in patients with HPV 16+ confirmed cancers comprising two parts: Phase I Dose Escalation and Phase II Dose Expansion.
• September 2023: Cue Biopharma announced a study of phase 1 clinical trials for CUE-101 and Keytruda. This is a multi-center, open-label, phase 1 dose escalation and expansion study evaluating the safety, anti-tumor effect, and immunogenicity of CUE-101 as monotherapy treatment in second line or CUE-101 Combination Therapy with Pembrolizumab in first line patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).
• September 2023: Pfizer announced a study of Phase 2 clinical trials for palbociclib and Cetuximab. The purpose of this study is to determine whether the combination of palbociclib with cetuximab is superior to cetuximab in prolonging overall survival in HPV-negative, cetuximab-naive patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
• June 2023: PDF Biotechnology Corp. announced a study of Phase 2 clinical trials for Pembrolizumab and PDS0101. VERSATILE-002 is a Phase 2, open-label, multicenter study of the efficacy and safety of PDS0101 administered in combination with pembrolizumab in adults with HPV16 and PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

 

Request a sample and discover the recent advances in HPV+ Recurrent/Metastatic Head and Neck Cancer Treatment Drugs @ HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Report

 

In the HPV+ Recurrent/Metastatic Head and Neck Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, HPV+ Recurrent/Metastatic Head and Neck Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

HPV+ Recurrent/Metastatic Head and Neck Cancer Overview

Cancers that are known collectively as head and neck cancers usually begin in the squamous cells that line the mucosal surfaces of the head and neck (for example, those inside the mouth, throat, and voice box). These cancers are referred to as squamous cell carcinomas of the head and neck. Head and neck cancers can also begin in the salivary glands, sinuses, or muscles or nerves in the head and neck, but these types of cancer are much less common than squamous cell carcinomas. Head and neck cancer symptoms may include a lump in the neck or a sore in the mouth or the throat that does not heal and may be painful, a sore throat that does not go away, difficulty in swallowing, and a change or hoarseness in the voice.

 

Find out more about HPV+ Recurrent/Metastatic Head and Neck Cancer Therapeutics Assessment @ HPV+ Recurrent/Metastatic Head and Neck Cancer Preclinical and Discovery Stage Products

 

HPV+ Recurrent/Metastatic Head and Neck Cancer Emerging Drugs Profile

• CUE 101: Cue Biopharma
• BNT 113: BioNTech

 

HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Therapeutics Assessment

There are approx. 5+ key companies which are developing the therapies for HPV+ Recurrent/Metastatic Head and Neck Cancer. The HPV+ Recurrent/Metastatic Head and Neck Cancer companies which have their HPV+ Recurrent/Metastatic Head and Neck Cancer drug candidates in the most advanced stage, i.e. phase II include, BioNTech.

 

DelveInsight’s HPV+ Recurrent/Metastatic Head and Neck Cancer pipeline report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

HPV+ Recurrent/Metastatic Head and Neck Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

 

HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

 

Learn more about the emerging HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Therapies @ HPV+ Recurrent/Metastatic Head and Neck Cancer Clinical Trials Assessment

 

Scope of the HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Report

• Coverage- Global
• HPV+ Recurrent/Metastatic Head and Neck Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• HPV+ Recurrent/Metastatic Head and Neck Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• HPV+ Recurrent/Metastatic Head and Neck Cancer Companies- BioNTech, Cue Biopharma, Hookipa Pharma, and others.
• HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Therapies- MEDI0457, Durvalumab, CUE-101, Keytruda, BNT113, Pembrolizumab, palbociclib, Cetuximab, and others.

 

Dive deep into rich insights for new drugs for HPV+ Recurrent/Metastatic Head and Neck Cancer Treatment, Visit @ HPV+ Recurrent/Metastatic Head and Neck Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. HPV+ Recurrent/Metastatic Head and Neck Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. HPV+ Recurrent/Metastatic Head and Neck Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Pre-Registration)
8. Drug Name : Company Name
9. Drug profiles in the detailed report…..
10. Last Stage Products (Phase III)
11. Drug Name : Company Name
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. BNT 113: BioNTech
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. HPV+ Recurrent/Metastatic Head and Neck Cancer Key Companies
21. HPV+ Recurrent/Metastatic Head and Neck Cancer Key Products
22. HPV+ Recurrent/Metastatic Head and Neck Cancer – Unmet Needs
23. HPV+ Recurrent/Metastatic Head and Neck Cancer – Market Drivers and Barriers
24. HPV+ Recurrent/Metastatic Head and Neck Cancer – Future Perspectives and Conclusion
25. HPV+ Recurrent/Metastatic Head and Neck Cancer Analyst Views
26. HPV+ Recurrent/Metastatic Head and Neck Cancer Key Companies
27. Appendix

 

For further information on the HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline therapeutics, reach out to HPV+ Recurrent/Metastatic Head and Neck Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment